Cigna Corporation
Cigna Corporation (CI) Stock Competitors & Peer Comparison
See (CI) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CI | $285.92 | +0.00% | 74.9B | 12.64 | $22.18 | +2.16% |
| UNH | $289.93 | +0.00% | 262.8B | 21.95 | $13.22 | +3.01% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.00% |
| CVS | $77.32 | +0.00% | 97.6B | 55.18 | $1.39 | +3.48% |
| ELV | $348.18 | +0.00% | 75.7B | 13.61 | $25.21 | +1.99% |
| HUM | $190.50 | +0.00% | 22.8B | 17.76 | $10.69 | +1.86% |
| CNC | $43.68 | +0.00% | 21.3B | -3.15 | -$13.72 | N/A |
| MOH | $148.24 | +0.00% | 7.8B | 16.95 | $8.91 | N/A |
| ALHC | $20.84 | +0.00% | 4.1B | -187.27 | -$0.11 | N/A |
| OSCR | $13.73 | +0.00% | 3.4B | -7.83 | -$1.69 | N/A |
Stock Comparison
CI vs UNH Comparison February 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.9B. In comparison, UNH has a market cap of 262.8B. Regarding current trading prices, CI is priced at $285.92, while UNH trades at $289.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.64, whereas UNH's P/E ratio is 21.95. In terms of profitability, CI's ROE is +0.15%, compared to UNH's ROE of +0.13%. Regarding short-term risk, CI is more volatile compared to UNH. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check UNH's competition here
CI vs ANTM Comparison February 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.9B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, CI is priced at $285.92, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.64, whereas ANTM's P/E ratio is 18.99. In terms of profitability, CI's ROE is +0.15%, compared to ANTM's ROE of +0.13%. Regarding short-term risk, CI is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check ANTM's competition here
CI vs CVS Comparison February 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.9B. In comparison, CVS has a market cap of 97.6B. Regarding current trading prices, CI is priced at $285.92, while CVS trades at $77.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.64, whereas CVS's P/E ratio is 55.18. In terms of profitability, CI's ROE is +0.15%, compared to CVS's ROE of +0.02%. Regarding short-term risk, CI is less volatile compared to CVS. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check CVS's competition here
CI vs ELV Comparison February 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.9B. In comparison, ELV has a market cap of 75.7B. Regarding current trading prices, CI is priced at $285.92, while ELV trades at $348.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.64, whereas ELV's P/E ratio is 13.61. In terms of profitability, CI's ROE is +0.15%, compared to ELV's ROE of +0.13%. Regarding short-term risk, CI is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check ELV's competition here
CI vs HUM Comparison February 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.9B. In comparison, HUM has a market cap of 22.8B. Regarding current trading prices, CI is priced at $285.92, while HUM trades at $190.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.64, whereas HUM's P/E ratio is 17.76. In terms of profitability, CI's ROE is +0.15%, compared to HUM's ROE of +0.07%. Regarding short-term risk, CI is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check HUM's competition here
CI vs CNC Comparison February 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.9B. In comparison, CNC has a market cap of 21.3B. Regarding current trading prices, CI is priced at $285.92, while CNC trades at $43.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.64, whereas CNC's P/E ratio is -3.15. In terms of profitability, CI's ROE is +0.15%, compared to CNC's ROE of -0.28%. Regarding short-term risk, CI is less volatile compared to CNC. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check CNC's competition here
CI vs MOH Comparison February 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.9B. In comparison, MOH has a market cap of 7.8B. Regarding current trading prices, CI is priced at $285.92, while MOH trades at $148.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.64, whereas MOH's P/E ratio is 16.95. In terms of profitability, CI's ROE is +0.15%, compared to MOH's ROE of +0.11%. Regarding short-term risk, CI is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check MOH's competition here
CI vs ALHC Comparison February 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.9B. In comparison, ALHC has a market cap of 4.1B. Regarding current trading prices, CI is priced at $285.92, while ALHC trades at $20.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.64, whereas ALHC's P/E ratio is -187.27. In terms of profitability, CI's ROE is +0.15%, compared to ALHC's ROE of -0.16%. Regarding short-term risk, CI is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check ALHC's competition here
CI vs OSCR Comparison February 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.9B. In comparison, OSCR has a market cap of 3.4B. Regarding current trading prices, CI is priced at $285.92, while OSCR trades at $13.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.64, whereas OSCR's P/E ratio is -7.83. In terms of profitability, CI's ROE is +0.15%, compared to OSCR's ROE of -0.39%. Regarding short-term risk, CI is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check OSCR's competition here
CI vs CLOV Comparison February 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.9B. In comparison, CLOV has a market cap of 1B. Regarding current trading prices, CI is priced at $285.92, while CLOV trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.64, whereas CLOV's P/E ratio is -18.36. In terms of profitability, CI's ROE is +0.15%, compared to CLOV's ROE of -0.17%. Regarding short-term risk, CI is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check CLOV's competition here
CI vs BHG Comparison February 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.9B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, CI is priced at $285.92, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.64, whereas BHG's P/E ratio is -0.12. In terms of profitability, CI's ROE is +0.15%, compared to BHG's ROE of -0.65%. Regarding short-term risk, CI is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check BHG's competition here
CI vs CABR Comparison February 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.9B. In comparison, CABR has a market cap of 12.1M. Regarding current trading prices, CI is priced at $285.92, while CABR trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.64, whereas CABR's P/E ratio is N/A. In terms of profitability, CI's ROE is +0.15%, compared to CABR's ROE of N/A. Regarding short-term risk, CI is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check CABR's competition here
CI vs BMGL Comparison February 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.9B. In comparison, BMGL has a market cap of 12M. Regarding current trading prices, CI is priced at $285.92, while BMGL trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.64, whereas BMGL's P/E ratio is -1.21. In terms of profitability, CI's ROE is +0.15%, compared to BMGL's ROE of -1.95%. Regarding short-term risk, CI is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check BMGL's competition here
CI vs MRAI Comparison February 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.9B. In comparison, MRAI has a market cap of 7M. Regarding current trading prices, CI is priced at $285.92, while MRAI trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.64, whereas MRAI's P/E ratio is -0.16. In terms of profitability, CI's ROE is +0.15%, compared to MRAI's ROE of +0.39%. Regarding short-term risk, CI is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check MRAI's competition here
CI vs NIVF Comparison February 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.9B. In comparison, NIVF has a market cap of 20.5K. Regarding current trading prices, CI is priced at $285.92, while NIVF trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.64, whereas NIVF's P/E ratio is N/A. In terms of profitability, CI's ROE is +0.15%, compared to NIVF's ROE of +1.17%. Regarding short-term risk, CI is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check NIVF's competition here
CI vs MGLN Comparison February 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.9B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, CI is priced at $285.92, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.64, whereas MGLN's P/E ratio is 8.49. In terms of profitability, CI's ROE is +0.15%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, CI is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check MGLN's competition here
CI vs GTS Comparison February 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 74.9B. In comparison, GTS has a market cap of 0. Regarding current trading prices, CI is priced at $285.92, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.64, whereas GTS's P/E ratio is 10.41. In terms of profitability, CI's ROE is +0.15%, compared to GTS's ROE of +0.07%. Regarding short-term risk, CI is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check GTS's competition here